Gross margin was 31.4%, compared to 
35.1% in 2022, impacted by product mix 
alongside a one-off positive impact in 2022 
of 
a 
customer 
bankruptcy 
related 
indemnities (FY22: 33.4% on a like-for-like 
basis)

Group order intake of EUR 267.2 million; PT 
and Other Accelerators order intake was 
EUR 200.1 million and Dosimetry order 
intake was EUR 67.1 million

Total Group net loss of EUR 9.1 million 
(2022: EUR 6.1 million profit), primarily 
driven by PT performance